Cargando…

Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy

Cardiac response to enzyme replacement therapy (ERT) in Fabry disease is typically assessed by measuring left ventricular mass index using echocardiography or cardiovascular magnetic resonance, but neither quantifies myocardial biology. Low native T1 in Fabry disease represents sphingolipid accumula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nordin, Sabrina, Kozor, Rebecca, Vijapurapu, Ravi, Augusto, João B., Knott, Kristopher D., Captur, Gabriella, Treibel, Thomas A., Ramaswami, Uma, Tchan, Michel, Geberhiwot, Tarekegn, Steeds, Richard P., Hughes, Derralynn A., Moon, James C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924943/ https://www.ncbi.nlm.nih.gov/pubmed/31826677 http://dx.doi.org/10.1161/CIRCIMAGING.119.009430

Ejemplares similares

The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage
por: Augusto, João B, et al.
Publicado: (2020)

Cardiac Phenotype of Prehypertrophic Fabry Disease
por: Nordin, Sabrina, et al.
Publicado: (2018)

Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2022)

Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease
por: Vijapurapu, Ravi, et al.
Publicado: (2023)

Increased cardiac involvement in Fabry disease using blood-corrected native T1 mapping
por: Nickander, Jannike, et al.
Publicado: (2023)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Atherosclerosis in Fabry Disease—A Contemporary Review
por: Roy, Ashwin, et al.
Publicado: (2021)

ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
por: Kozor, Rebecca, et al.
Publicado: (2016)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis
por: Baig, Shanat, et al.
Publicado: (2020)

Progressive cardiac involvement in a compound heterozygote Fabry patient: a case report
por: McConnell, Eliza Jeanette, et al.
Publicado: (2018)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Impact of SARS‐CoV‐2 (COVID‐19) pandemic on patients with lysosomal storage disorders and restoration of services: experience from a specialist centre
por: Ramaswami, Uma, et al.
Publicado: (2021)

Update on role of agalsidase alfa in management of Fabry disease
por: Ramaswami, Uma
Publicado: (2011)

Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel
por: Stepien, Karolina M., et al.
Publicado: (2023)

A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease
por: Kozor, Rebecca, et al.
Publicado: (2015)

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
por: Beck, Michael, et al.
Publicado: (2017)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group
por: Gal, Andreas, et al.
Publicado: (2011)

Clinical prodromes of neurodegeneration in Anderson-Fabry disease
por: Löhle, Matthias, et al.
Publicado: (2015)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
por: Beck, Michael, et al.
Publicado: (2022)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

Apical Hypertrophic Cardiomyopathy: The Variant Less Known
por: Hughes, Rebecca K., et al.
Publicado: (2020)

A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
por: Kistler, Andreas D., et al.
Publicado: (2011)

Translation of quality of life scale for pediatric patients with Fabry disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
por: Ramaswami, Uma, et al.
Publicado: (2012)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
por: Parini, Rossella, et al.
Publicado: (2020)

Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease
por: Sado, Daniel, et al.
Publicado: (2013)

Estimation of Health State Utility Values in Fabry Disease Using Vignette Development and Valuation
por: Hughes, Derralynn, et al.
Publicado: (2023)

Lysosomal Storage Disorders and Malignancy
por: Pastores, Gregory M., et al.
Publicado: (2017)

Alström syndrome: a paradigm for diffuse fibrosis and clinical progression
por: Edwards, Nicola C, et al.
Publicado: (2013)

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
por: Hughes, Derralynn A., et al.
Publicado: (2019)

Measures to mitigate disruption due to the COVID-19 pandemic of the MODIFY phase 3 pivotal trial in patients with Fabry disease
por: Frey, Aline, et al.
Publicado: (2021)

Paediatric Fabry disease: prognostic significance of ocular changes for disease severity
por: Kalkum, Gisela, et al.
Publicado: (2016)

Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance
por: Pica, Silvia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qhdojh635pmhrgknpl17fpvce9